Skip to main content

Saturn Medic

Clinical Subject Page

Type 1 Diabetes Mellitus (T1DM)

Type 1 Diabetes Mellitus (T1DM) is a chronic metabolic disease caused by autoimmune destruction of pancreatic beta cells, resulting in an absolute deficiency of insulin and persistent hyperglycemia

Also called

Insulin-dependent diabetes mellitus (IDDM)

ICD-10

E10

Specialty

Endocrine

Onset

Chronic

Reviewed

August 2026

On This Page

Overview

  • Type 1 Diabetes Mellitus (T1DM) occurs when pancreatic beta cells are destroyed, leading to little or no endogenous insulin production.
  • Without insulin, glucose cannot be adequately utilized by insulin-dependent tissues and hepatic glucose production remains elevated, resulting in hyperglycemia.
  • Patients require lifelong insulin replacement. Diabetic ketoacidosis (DKA) is an important acute complication

Etiology & Risk Factors

Etiology:

The main cause is immune-mediated destruction of pancreatic beta cells.

The disease usually develops through a combination of:

  • Genetic susceptibility
  • Autoimmune mechanisms
  • Environmental triggers

Common pancreatic autoantibodies include:

  • Glutamic acid decarboxylase 65 (GAD65) antibodies
  • Insulin autoantibodies (IAA)
  • Insulinoma-associated-2 (IA-2) antibodies
  • Zinc transporter 8 (ZnT8) antibodies

A minority of patients have idiopathic Type 1 Diabetes Mellitus without evidence of autoimmunity.

 

-Inheritance:

Type 1 Diabetes Mellitus (T1DM) is not inherited in a simple Mendelian pattern.

It has a strong genetic component, particularly involving human leukocyte antigen (HLA) genes, but environmental factors also contribute.

 

-Risk Factors:

  • Family history of Type 1 Diabetes Mellitus
  • Genetic susceptibility, particularly certain HLA haplotypes
  • Personal or family history of autoimmune disease
  • Younger age, although T1DM can occur at any age
  • Certain environmental or infectious triggers may contribute

Pathophysiology

Genetic susceptibility + environmental factors → autoimmune activation → pancreatic beta-cell destruction → progressive loss of insulin secretion → absolute insulin deficiency → decreased peripheral glucose uptake + increased hepatic glucose production → hyperglycemia → increased lipolysis → ketone production → risk of diabetic ketoacidosis

Clinical Presentation

-Classic symptoms Of Type 1 Diabetes Mellitus (T1DM) include:

  • Polyuria
  • Polydipsia
  • Polyphagia
  • Unintentional weight loss
  • Fatigue
  • Weakness
  • Blurred vision

-Other possible symptoms:

  • Nocturia
  • Recurrent infections
  • Poor wound healing
  • Abdominal pain
  • Nausea and vomiting, particularly with diabetic ketoacidosis
  • Altered consciousness in severe diabetic ketoacidosis

-Signs:

  • Weight loss
  • Dehydration
  • Tachycardia
  • Hypotension in severe dehydration
  • Hyperglycemia
  • Fruity or acetone breath in ketoacidosis
  • Deep, rapid breathing (Kussmaul respirations) in severe ketoacidosis
  • Reduced level of consciousness in severe DKA

-Severe Disease:

  • Severe insulin deficiency may lead to diabetic ketoacidosis (DKA).

Important findings include:

  • Nausea and vomiting
  • Abdominal pain
  • Dehydration
  • Tachycardia
  • Hypotension
  • Kussmaul respirations
  • Fruity breath

History Taking

-Ask about:

  • Polyuria
  • Polydipsia
  • Polyphagia
  • Weight loss
  • Fatigue
  • Blurred vision
  • Nocturia
  • Recurrent infections
  • Symptoms of DKA
  • Previous episodes of hyperglycemia or DKA
  • Insulin use and adherence
  • Insulin dose and administration technique
  • Blood glucose monitoring
  • Continuous glucose monitoring, if used
  • Episodes of hypoglycemia
  • Dietary habits

Physical Examination

-General Examination

  • Blood pressure
  • Heart rate
  • Respiratory rate
  • Temperature
  • General nutritional status
  • Level of consciousness

-During suspected DKA, specifically assess for:

  • Dehydration
  • Tachycardia
  • Hypotension
  • Kussmaul respirations

System-Specific Examination

-Cardiovascular:

  • Blood pressure
  • Peripheral pulses
  • Cardiovascular risk assessment

-Neurological:

  • Mental status
  • Peripheral neuropathy assessment in established disease

-Eyes:

  • Visual acuity
  • Retinal examination for diabetic retinopathy

-Feet:

  • Pulses
  • Sensation
  • Ulceration

Investigations

-Biochemistry / Specific Tests

-Plasma glucose:

  • Diabetes can be diagnosed using standard diagnostic criteria, including:
  • Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L)
  • 2-hour plasma glucose during a 75-g oral glucose tolerance test ≥200 mg/dL (11.1 mmol/L)
  • Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with classic symptoms of hyperglycemia or hyperglycemic crisis

HbA1c ≥6.5%, using an appropriate standardized laboratory method

-Glycated Hemoglobin (HbA1c)

  • Reflects average glycemic exposure over approximately the previous 2–3 months.

Used for diagnosis in appropriate clinical settings and for monitoring long-term glycemic control.

-C-peptide

  • Reflects endogenous insulin production.

Diagnosis

–Diagnosis requires evidence of diabetes mellitus, using accepted glucose or HbA1c criteria.

-Type 1 Diabetes Mellitus (T1DM) is supported by:

  • Clinical features of insulin deficiency
  • Low endogenous insulin production/C-peptide
  • Positive diabetes-related autoantibodies
  • Typical presentation with ketosis or DKA

The diagnosis should also consider other forms of diabetes when the presentation is atypical.

Home / Home / Clinical Cases / Endocrine System Clinical Cases / Type 1 Diabetes Mellitus (T1DM)
Related Topics

Management

1. First-Line / Emergency Management

For stable newly diagnosed T1DM:

  • Begin insulin replacement
  • Educate the patient about glucose monitoring, insulin administration, nutrition, exercise, and hypoglycemia prevention.

-For diabetic ketoacidosis:

  • Rapid clinical assessment
  • Intravenous fluids
  • Intravenous insulin
  • Electrolyte monitoring and replacement, especially potassium
  • Identification and treatment of precipitating factors
  • Frequent monitoring of glucose, ketones, electrolytes, and acid-base status

2. Definitive Treatment

Lifelong insulin therapy is the fundamental treatment for Type 1 Diabetes Mellitus.

-Common insulin strategies include:

  • Multiple daily injections using basal and bolus insulin
  • Continuous subcutaneous insulin infusion using an insulin pump
  • Automated insulin delivery systems when appropriate

3. Medical Treatment

Insulin is essential.

Treatment generally includes:

  • Basal insulin to provide background insulin coverage
  • Prandial/bolus insulin to cover meals
  • Additional correction doses when required

Glucose monitoring

  • Self-monitoring of blood glucose

Continuous glucose monitoring (CGM), when available and appropriat

4. Supportive Management

  • Diabetes education
  • Individualized nutrition plan
  • Regular physical activity
  • Hypoglycemia education
  • Sick-day management plan
  • Glucagon availability for severe hypoglycemia
  • Regular screening for diabetic complications

Complications

-Acute Complications:

  • Diabetic ketoacidosis
  • Hypoglycemia
  • Severe hypoglycemia
  • Hyperglycemia

-Chronic Complications:

Microvascular:

  • Diabetic retinopathy
  • Diabetic nephropathy
  • Diabetic neuropathy

Macrovascular:

  • Coronary artery disease
  • Cerebrovascular disease
  • Peripheral arterial disease

Other:

    • Cardiovascular disease
    • Foot ulcers
    • Increased susceptibility to infections
    • Associated autoimmune diseases

Prognosis

With modern insulin therapy, glucose monitoring, and appropriate complication screening, people with Type 1 Diabetes Mellitus (T1DM)  can achieve good long-term outcomes.

Prognosis depends mainly on:

  • Long-term glycemic control
  • Frequency and severity of hypoglycemia
  • Blood pressure and lipid control
  • Development of renal, retinal, neurological, and cardiovascular complications

Key Points / Clinical Pearls

  • Type 1 Diabetes Mellitus (T1DM) is caused by destruction of pancreatic beta cells.
  • It results in absolute insulin deficiency.
  • Most cases are caused by an autoimmune process.
  • Patients require lifelong insulin therapy.
  • Classic symptoms are polyuria, polydipsia, polyphagia, and weight loss.
  • Diabetic ketoacidosis can be the first presentation.
  • Diabetes is diagnosed using plasma glucose and/or HbA1c diagnostic criteria.
  • C-peptide helps assess endogenous insulin production.
  • Diabetes-related autoantibodies can support classification as T1DM.
  • Basal-bolus insulin therapy is a common treatment strategy.
  • American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). Diabetes Care .
  • American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). Diabetes Care .
  • Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2021;44(11):2589-2625. Diabetes Care .
  • American Diabetes Association. Type 1 Diabetes . American Diabetes Association.
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Type 1 Diabetes . National Institutes of Health.
  • International Society for Pediatric and Adolescent Diabetes (ISPAD). ISPAD Clinical Practice Consensus Guidelines .